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Identification of structural domains in inter-a-trypsin inhibitor in-
volved in calcium oxalate crystallization. The urinary glycoprotein that
inhibits calcium oxalate (CaOx) crystallization in vitro shows a structural
similarity to urinary trypsin inhibitor (UTI; recently termed bikunin), the
light chain of inter-a-trypsin inhibitor (IaI). The functional domains of IaI
involved in its inhibitory activity of CaOx crystallization have been
investigated using isolated intact domains of IaI produced from controlled
proteolytic digests of the protein. The fragments investigated include the
heavy chains of IaI, UTI, chondroitinase AC-treated UTI, and the
carboxyl-terminal domain of UTI (termed HI-8). The effects of IaI and its
fragments on the inhibitory activity of CaOx crystallization were evaluated
in vitro using CaOx crystal aggregation and growth assays, and seeded
crystal generation assay as well as using crystal matrix protein generation
assay. UTI, but not the heavy chains of IaI, had a discernible effect on
CaOx crystallization inhibitory activity. Less requirement of the carbohy-
drate moiety of UTI is implicated by the observation that chondroitinase
AC-treated UTI fragment was also found to inhibit CaOx crystallization
with almost the same activity as UTI. HI-8 also efficiently inhibited CaOx
crystallization, while IaI showed a weak inhibitory activity. The results are
almost consistent with a seed crystal generation assay and a crystal
adsorption inhibition assay, in which IaI or its derivatives inhibits pro-
thrombin fragment 1 (F1) adsorption to CaOx crystals. In conclusion,
these results suggest that the part of the IaI protein responsible for
inhibition of CaOx crystallization is the carboxyl-terminal domain of UTI.
Described in 1993 by Atmani et al [1], uronic-acid-rich protein
(UAP) is a urinary glycoprotein that inhibits calcium oxalate
(CaOx) crystallization in vitro. They demonstrated that UAP
belongs to the inter-a-trypsin inhibitor (IaI) family [2–4]. Human
IaI is comprised of three genetically different polypeptide chains:
two heavy chains and one light chain, which was first described by
Steinbuch and Loel [5]. The light chain is also referred to as the
urinary trypsin inhibitor (UTI), and also was recently termed
“bikunin” (Fig. 1). IaI occurs at a concentration near 0.5 mg/ml
plasma and accounts for less than 5% of the total trypsin
inhibitory activity [6]. It appears that members of IaI family are
involved in urolithiasis by modulating CaOx crystallization [7].
Protein inhibitors of stone formation play the major role in the
natural defence against nephrocalcinosis [8]. Besides the IaI
family, there are several protein inhibitors of CaOx crystallization
such as glycosaminoglycans and Tamm-Horsfall protein (THP)
[9–20]. Due to the progress made in protein chemistry and
molecular biology, more information will be available about the
inhibitory proteins including their purification, identification as
well as their synthesis and biological activity.
We have previously reported that a highly purified UTI, but not
IaI, inhibits not only tumor cell invasion in an in vitro assay, but
also production of experimental and spontaneous lung metastasis
in an in vivo mouse model [21]. Proteolytic fragments of IaI that
consist of a single module or two modules in combination were
isolated and characterized in order to study structure-function
relationship [22]. We isolated a proteolytic fragment (termed
HI-8) from trypsin digests of human UTI. This fragment consisted
of the carboxyl-terminal, second Kunitz-type domain and retained
trypsin inhibitory activity [23]. Based on studies of UTI fragments,
we demonstrated that HI-8 promotes the inhibition of tumor cell
invasion and metastasis with essentially the same affinity as UTI.
All these data allow us to conclude that inhibition of tumor cell
invasion and metastasis is mediated by the carboxyl-terminal
domain of UTI [24].
Besides protease inhibiting and anti-metastatic activities, UTI
has additional functions including the prevention of cytokine
production or inhibition of cellular calcium influx [25–27].
Namely, UTI was found to inhibit interleukin-8 gene expression
induced by lipopolysaccharide (LPS) in HL60 cells [27]. UTI also
inhibited increase of cytosolic calcium stimulated by LPS but not
by the calcium ionophore A23187 [25, 26]. The cell membrane
may be the site of action of UTI, and the effect of UTI may be due
to inhibition of calcium influx or mobilization [27]. We have been
investigating the relationship between the effectiveness of the
inhibition of tumor cell invasion and metastasis and the calcium-
binding properties in UTI molecule.
Our attention was focused on a urinary glycoprotein inhibitor,
uronic-acid-rich protein (UAP), that has been isolated from the
urine and showed several structural similarities with UTI [1]. To
clarify the active domains within the IaI molecule, IaI, heavy
chains of IaI, UTI, chondroitinase AC-treated UTI, and the
carboxy-terminal domain of UTI (HI-8) were purified and their
CaOx crystallization inhibitory activity was studied. The results
demonstrate that the fragment consisting of the carboxyl-termi-
nal, second Kunitz-type module accounts for most of the inhibi-
tory activity of CaOx crystallization.
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METHODS
Purification and preparation of IaI and its derivatives
Human IaI was purified as described previously [28, 29]. A
highly purified preparation of human UTI was kindly supplied by
Mochida Pharmaceutical Co. (Tokyo, Japan). A trypsin-Sepha-
rose affinity column was used to obtain purified HI-8. HI-8 was
kindly provided by Dr. D. Sugino (Nissin Food Product Co.,
Kusatsu, Shiga, Japan) [30].
IaI and UTI were treated separately with chondroitinase AC as
described by Sørensen et al [31]. Proteins were incubated with
chondroitinase AC (0.042 U/100 mg protein) for 16 hours at 37°C
in the buffer (0.25 M Tris, 0.29 M sodium acetate, 0.25 M sodium
chloride, pH 8.0). The degradation products were applied to a
Sephadex G-100 gel chromatography. Each fraction was pooled
and amino-terminal amino acid sequencing as well as SDS-PAGE
was carried out to obtain purified heavy chains of IaI or deglyco-
sylated UTI, respectively.
IaI and UTI were purified to homogeneity from human serum
and urine, respectively. SDS-PAGE under non-reducing condi-
tions showed that UTI migrated as a polydisperse molecular
weight 40 kDa band. By electroblotting directly from SDS-PAGE,
we identified the one component on the basis of the amino acid
sequences. NH2-terminal sequencing of the 40 kDa UTI prepa-
ration yielded only one sequence 1AVLPQEEEG. In addition,
UTI was homogenous by SDS-PAGE prior to and after deglyco-
sylation with chondroitinase AC. It had an apparent molecular
weight of 40 kDa prior to deglycosylation; this was reduced to 28
kDa after chondroitinase AC treatment. The 8 kDa COOH-
terminal fragment of UTI (HI-8) were prepared from purified
UTI by trypsin proteolysis. HI-8 remained associated with the
trypsin affinity matrix and was purified to homogeneity by SDS-
PAGE and amino acid analysis. It is thus impossible that chon-
droitinase AC-treated UTI and HI-8 contain residual intact UTI
in the purified protein mixtures.
Calcium oxalate monohydrate crystal growth inhibition
Calcium oxalate monohydrate (COM) crystal growth inhibitory
activity of purified proteins was assayed on a crystallization model
in vitro as previously described [32]. For this experiment, IaI,
heavy chains of IaI, UTI, chondroitinase AC-treated UTI, and
HI-8 were purified and studied. Seed crystal slurries were pre-
pared by the suspension of 1.5 mg/ml of the crystals in a 50 mM
sodium acetate buffer, pH 5.7, containing 96 mM NaCl. Slurries
were allowed to equilibrate in buffer, with stirring, for two hours
prior to use. The crystal growth reaction was initiated by the
addition of 3 ml of slurry to 33 ml of a metastable calcium oxalate
solution containing 0.833 mM CaCl2 and 0.167 mM sodium oxalate
along with a tracer of [14C]oxalate in the presence of various
concentrations of IaI or its derivatives (0 to 1025 M). The final
seed crystal concentration was 0.125 mg/ml. The solutions were
magnetically stirred in a constant temperature both at 37°C. After
a 30 minute incubation, 1 ml aliquots were removed and filtered
through Millipore filter (0.2 mm) and the level of [14C]oxalate
radioactivity (count per min in 100 ml) was determined in a liquid
scintillation counter. Thus, the rate of loss of oxalate from
solution was calculated.
Inhibition of calcium oxalate crystallization
In a parallel experiment, CaOx crystallization inhibitory activity
of purified proteins was assayed on a crystallization model in vitro
as previously described [3, 6]. One milliliter of 2 mM calcium
chloride in Tris 0.05 M, NaCl, 0.15 M, pH 7.3, with a trace of 45Ca
was pipetted into tubes containing different amount of purified
proteins (IaI or its derivatives; 0 to 1025 M). The assay was started
by adding 1 ml of 2 mM ammonium oxalate in Tris 0.05 M, NaCl
0.15 M, pH 7.3, for one hour with stirring. Tubes were then
centrifuged at 2000 g for five minutes and 0.5 ml supernatant was
withdrawn for radioactivity determination [5].
Fig. 1. Schematic representation of IaI and its
derivatives. IaI protein is composed of two
heavy chains (HC1 and HC2) and one light
chain associated with chondroitin sulfate. The
light chain, also known as bikunin or urinary
trypsin inhibitor (UTI), has two active Kunitz-
type protease inhibitor domains and the
inhibitory activity of the IaI protein entirely
depends on UTI. Schematic representation of
the biosynthesis of IaI and derivatives was
described [29, 38, 39].
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Seed crystal formation assay
Inhibition of CaOx monohydrate (COM) crystals: Preparation of
seed crystals and inhibition of crystals with inhibitors. Seed crystals
were prepared as described previously [13]. Seed crystals of COM
were crystallized from a supersaturated solution prepared by
mixing equal parts 1.0 mM sodium oxalate and 1.0 mM calcium
chloride, both pre-equillibrated to 60°C and cooled after mixing to
30°C over 48 hours. After the two cycles, the solutions were
evapolated at 30°C to one-half of their original volume. The
crystals were harvested by centrifugation (1,000 g), the superna-
tant was removed, and the crystals were washed with ethanol and
dried at 37°C.
Seed crystals (4 mg) were incubated with a 1.0 ml solution of
either Tris-buffered saline (TBS buffer) or purified proteins (1
mM) in the presence of a saturated CaOx solution, shaken for 30
minutes at 37°C, and centrifuged, and the supernatant was
removed. Seed crystals treated with each fragment were observed
by light microscope.
Crystal matrix protein found in the organic matrix of CaOx
crystals generated from urine
Urine was collected for 24 hours from normal healthy volun-
teers in the presence of sodium azide (0.02% wt/vol) and kept at
4°C throughout the collection period. The urine was centrifuged
at 10,000 g and filtered (0.22 mm; Millipore, MA, USA). We
confirmed complete dissolution of the crystals prior to examina-
tion of the matrix proteins. CaOx crystals were generated by
adding sodium oxalate while the urine was shaking in a water bath
at 37°C in the presence or absence of proteins (1 mM) [33].
SDS-PAGE and Western blot
CaOx crystals were harvested, washed, dried, weighed, and
demineralized with 0.25 mol/liter EDTA, pH 8.0. Protein samples
for SDS-PAGE were prepared by mixing equal parts samples
buffer and the demineralized solution. Protein samples were
reduced with b-mercaptoethanol and analyzed by electrophoresis
in 12% gels. Protein samples were transferred to polyvinylidine
difluoride (PVDF) membranes using Semi-dry transblot appara-
tus (40 mA/gel, 90 min, 23°C; Marysol, Tokyo, Japan). These
membranes were blocked with 2% BSA in TBS buffer, pH 8.5 by
incubating for one hour. They were immunolabeled with rabbit
anti-human prothrombin antibody (RAh/PTh; Nordic Immunol-
ogy, Tilburg, The Netherlands), diluted 1: 1000 in TBS containing
2% bovine serum albumin (BSA) for one hour at 23°C. Appro-
priate biotinylated secondary antibody was subsequently applied
for one hour at 23°C, followed by avidin-peroxidase (1: 1000, 1 hr,
23°C). The membranes were washed seven times with TBS
containing 0.05% Tween 20 after each incubation. The color
reaction was developed with 4-chloro-1-naphthol in the presence
of 0.2% H2O2 to give a purple precipitate.
Inhibitory activity of calcium oxalate crystal growth and
aggregation (flow cytometric analysis)
Measurement of CaOx crystal growth. One milliliter of a solution
(2 mM) of sodium oxalate was added to 1 ml of a solution (2 mM)
of CaCl2 preincubated with the purified protein (0 to 10 mM).
Metastable solution without the purified protein was routinely
included as a standard control in each incubation. Solutions were
incubated at 37°C for one hour and the crystal size distributions
recorded. The size distribution of the particles was recorded using
flow cytometry (EPICS, Coulter). Forward (FS) and side (SS)
light scatter were measured as an index of particle size and as a
difference of particle structure, respectively. All data were col-
lected using logarithmic amplification (LFS and LSS). The data
were collected in list mode files and analyzed later. The gate for
the microparticle population is shown in region 1 (Fig. 4). The
effect of IaI and its derivatives on crystal growth and aggregation
was compared at a concentration of 1.0 mM. Each experiment was
performed three times, and from the crystal diameter (Forward
Scatter; Y-axis) the extents of crystal growth were quantified
independently. Crystal growth was expressed as the cumulative
increase in crystal diameter. The size of the microparticles was
estimated by comparing their forward light scatter with that of
reference particles ranging from 0.1 to 10 mm in diameter.
Alteration to the left side in the X-axis indicates that the surface
of crystal particle is flat and unaccompanied by crystallites,
whereas shift to the right shows that the surface of particle is
uneven; crystals are covered with tiny crystallites.
RESULTS
The process of nephrolithiasis results from supersaturation with
respect to urinary salts including CaOx and from crystal retention
in the urinary tract. Urinary inhibitors are involved in the control
of these phenomena [20]. Several biochemical and immunological
studies confirmed the identity of a certain urinary inhibitor as
urinary bikunin [1–4, 6]. Therefore, it appears that members of
IaI family are involved in urolithiasis by modulating CaOx
crystallization.
CaOx crystallization may begin de novo from a supersaturated
solution. Once CaOx crystals have formed, they may serve as
effective sites for further CaOx crystallization. Urine inhibits
CaOx crystallization just as it inhibits growth and aggregation [13].
Fig. 2. Calcium oxalate (CaOx) crystallization inhibitory activity of IaI,
heavy chains of IaI, UTI, chondroitinase-treated UTI, and HI-8. CaOx
monohydrate crystal growth inhibition assay with a tracer of [14C]oxalate:
Calcium and oxalate were mixed with a trace amount of [14C]oxalate in the
presence of IaI and its derivatives (0 to 1025 M). Symbols are: (F) IaI; (M)
heavy chains of IaI; (E) UTI; (f) chondroitinase AC-treated UTI; ()
HI-8. Results are the mean of two experiments, carried out on triplicate
assays. Data are mean 6 SD.
Kobayashi et al: UTI inhibits CaOx crystal growth 1729
We examined whether IaI and its derivatives can inhibit CaOx
crystallization under conditions of marked supersaturation.
CaOx crystallization inhibitory activity of purified proteins was
tested with a tracer of [14C]oxalate. CaOx crystallization inhibitory
activity progressively increased with increasing protein concentra-
tions. UTI, chondroitinase AC-treated UTI, and HI-8 were potent
inhibitors of CaOx crystallization while IaI and heavy chains of
IaI were less inhibitory (Fig. 2). UTI at 1 3 1026 M inhibited
crystallization by 60%, not dramatically different from chondroiti-
nase-treated UTI and HI-8, whereas inhibition of IaI and heavy
chains of IaI at the same concentration was only 17% and 10%,
respectively. Consequently, these results indicate that the CaOx
crystallization inhibitory activity of the IaI family is supported by
the peptide chain and resides in the carboxyl-terminus of UTI. It
seems that UTI or its carboxyl-terminal fragment, HI-8, is an
efficient inhibitor of CaOx crystal formation and IaI may be a
weak inhibitor of CaOx crystal growth.
In a separate experiment, the CaOx crystallization inhibitory
activity of purified proteins was also assayed with a trace of 45Ca
on a crystallization model in vitro. UTI, chondroitinase-treated
UTI and HI-8 at the concentrations of 1026 M inhibited crystal-
lization by 73%, 59% and 51%, whereas inhibition of IaI and
heavy chains of IaI was only 20% and 7%, respectively (data not
shown). These results also showed that UTI, chondroitinase
AC-treated UTI and HI-8 were potent inhibitors of CaOx crystal
growth while IaI and the heavy chains of IaI were less inhibitory.
Seed crystals (4 mg) were incubated with a 1.0 ml solution of
either Tris buffer or purified proteins (1 mM) in the presence of a
saturated CaOx solution, shaken for 30 minutes at 37°C (Fig. 3).
After a 30 minute incubation, the original seed crystals were large
in size. In contrast, seed crystals treated with UTI were small. In
a parallel experiment, we confirmed that UTI, chondroitinase
AC-treated UTI and HI-8 were strong inhibitors of CaOx crystal
growth, while IaI and heavy chains of IaI were less inhibitory.
The effect of IaI and its derivatives on CaOx crystal growth was
tested using a standard seeded crystallization system, and its effect
was quantified by use of particle size analysis and a flow cytom-
etry. Figure 4A illustrates the flow cytometric analysis on the
effect of UTI on crystal growth. In the controls, CaOx crystal
diameter increased rapidly after a 30-minute incubation period
[Y-axis indicates logarithmic forward scatter (LFS); median par-
ticle size 5 40.6 mm (panel 1)]. UTI inhibited CaOx crystal growth
in a dose-dependent manner. At the concentration of 1 mM (Fig.
4A, panel 3), UTI strongly inhibited crystal growth. In addition,
the effect of IaI and its derivatives on crystal growth was
examined (Fig. 4B). The change of relative crystal growth was
Fig. 3. Seed crystals after incubation with and without IaI or its derivatives. Light micrographs of crystal deposited. (A) Typical CaOx crystals. The
crystals were precipitated from seeded CaOx crystals supplemented with 1 mM IaI (B), heavy chains of IaI (C), UTI (D), chondroitinase AC-treated
UTI (E), and HI-8 (F).
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plotted in relation to the concentrations of IaI and its derivatives.
Again, it was confirmed that UTI, chondroitinase AC-treated UTI
and HI-8 were potent inhibitors of CaOx crystal growth, while IaI
was less inhibitory and the heavy chains of IaI were not inhibitory
at all. The treatment with chondroitinase AC had no effect on this
inhibitory activity.
Crystal matrix protein (CMP) is the predominant protein found
in the organic matrix of CaOx crystals generated from urine and
is reported to be a urinary form of F1, a degradation product of
prothrombin possessing the domain rich in g-carboxyglutamic
acid [19]. We examined whether prothrombin degradation was
detected in extracts of crystals precipitated from urine in the
presence of IaI or its derivatives. The SDS-PAGE followed by
Western blot patterns of the proteinaceous material extracted
from the CaOx crystals generated in the presence or absence of
purified proteins are illustrated in Figure 5. The extracted pro-
teins were labeled with a polyclonal antibody to prothrombin. It
has been published previously that the most abundant protein in
crystals generated in urine is CMP, which has a molecular weight
of 31 kDa [19]. The anti-prothrombin antibody reacted strongly
with this protein as shown in Figure 5, lane 1 of the Western blot.
The 31 kDa prothrombin fragment was strongly detected in
extracts of crystals precipitated from urine in the presence of IaI
(lane 1) or heavy chains (lane 2). The extract from crystals
generated in urine in the presence of UTI (lane 3) and chondroiti-
nase-treated UTI (lane 4) did not contain the 31 kDa protein.
However, this band was weakly detected in extracts in the
presence of HI-8. The conclusion that HI-8 is a potent inhibitor
could not appear to be justified by the crystal matrix protein assay.
DISCUSSION
IaI is a plasma Kunitz-type serine protease inhibitor that
directly inhibits trypsin, chymotrypsin, plasmin, and granulocyte
elastase [22, 23]. Liver has been thought to be the source of IaI
and UTI. After they are synthesized in the liver, UTI is thought to
be secreted into plasma as the light chain of IaI, which consists of
two heavy chains and one light chain. UTI also exists as a free
form in plasma [34]. In normal human plasma, IaI and UTI exist
as the full-length molecule and as the glycosylated light chain
form, respectively. A novel pathway for internalization of IaI has
been characterized [35]. The intact IaI is bound to the pericellular
matrix-bound hyaluronic acid through heavy chains of IaI, where
IaI is cleaved between the heavy chains and UTI on the cell
surface [38]. UTI may be, in part, endocytosed and degraded [36]
or released into culture medium. UTI, but not IaI, was originally
found in urine. UTI is excreted in urine at a rate of several
miligrams per day from healthy subjects [37] or at a concentration
of about 5 3 1027 M (unpublished data; Kobayashi et al).
Fig. 3. Continued.
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Although some information is available, the physiological func-
tion of IaI and UTI is still obscure. It has also been reported that
mast cells contain and secrete trypstatin, which is identical to the
carboxyl-terminal portion of UTI, HI-8 [38, 39]. More recently, a
urinary glycoprotein that inhibits CaOx crystallization in vitro
shows a structural similarity to UTI [6, 7]. The purpose of this
study was to examine the importance of the UTI and its fragments
in inhibiting CaOx crystallization. To identify the active domain
within IaI molecule, IaI and its derivatives were purified and
studied. We assayed the inhibitory activity of these purified
proteins on CaOx crystallization and growth as well as on crystal
matrix protein generation.
The results demonstrate that an intact second Kunitz-type
domain within UTI molecule is required for inhibitory activity of
CaOx crystallization. HI-8, which contains the second Kunitz-type
domain and lacks the first Kunitz-type domain, inhibits trypsin
and chymotrypsin. The isolated heavy chains alone did not inhibit
CaOx crystallization, whereas the intact HI-8 region accounts for
most of the CaOx crystallization inhibitory activity. The observa-
tion that chondroitinase AC-treated UTI also inhibits crystalliza-
tion, indicated that there was no requirement for the carbohydrate
chain within the UTI molecule for inhibition of CaOx crystalliza-
tion. Chondroitinase-treated UTI and HI-8 inhibit CaOx crystal-
lization with almost the same affinity as UTI. This finding implies
that proteolytic degradation of the first Kunitz-type domain from
UTI does not affect the nature of the inhibitory activity of CaOx
crystallization by UTI. These data allow us to conclude that UTI
is present in the urine at the concentrations (5 3 1027 M) that
inhibit urinary crystallization.
The inhibitory effect of UTI was compared with other estab-
lished components of urine such as citrate, Tamm-Horsfall pro-
tein and albumin. Kok et al [40] reported that citrate was found to
be the most potent inhibitor at concentrations likely to be present
in normal urine. Sidhu et al [41] also reported that citrate was a
strong inhibitor of calcium oxalate monohydrate seed crystal
growth and caused a 50% decrease in crystal growth at 285 mM.
Ryall et al [42] have shown, however, that chondroitin sulfate,
human serum albumin and Tamm-Horsfall protein had a minor
effect on the crystal growth inhibitory activity. In the present
study, HI-8 caused a 50% decrease in CaOx crystallization
inhibitory activity at about 1 mM, in a seeded metastable CaOx
solution assay at , 0.1 mM and in a crystal matrix protein
generation assay at . 1 mM, respectively. The disagreement in
these findings related to the compounds may possibly be a
consequence of differences in the methodology used. Collectively,
the results of our study have demonstrated that UTI and HI-8
strongly inhibit the growth and aggregation of CaOx crystals
compared with other established components of urine.
In this context it is noteworthy that inhibition of calcium
adsorption to crystals by UTI is consistent with a model in which
Fig. 3. Continued.
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UTI is required for catalytically competent binding of calcium
ions to CaOx crystals. More attention is required to understand
the mechanism by which UTI and HI-8 act as a potent inhibitor of
CaOx crystallization. UTI, but not IaI, is thought to be a calcium
binding protein (Kanayama et al, unpublished data). It is likely
that the inhibitory action depends on binding of the inhibitor to
sites of growth on the surface of the seed crystals. UTI has a much
greater number of sites for binding than IaI on the same crystal
surface area. It is also probable that the weak inhibitory influence
of IaI on crystal growth can be ascribed to its physical character-
istics, which by steric hindrance, rather than by physicochemical
adsorption, cannot prevent newly formed single crystals from
becoming close enough to allow aggregate formation. These may
be the reasons why the parent molecule, IaI, is much less active
than UTI or HI-8.
Aside from the mechanism of calcium binding to UTI, how
does calcium binding to proteins belonging to the IaI family result
in inhibition of CaOx crystallization? One possible model to
explain this effect is as follows: bound UTI molecule inhibits
calcium binding to crystals via an electrostatic effect, since HI-8
contains the positively charged cluster within the molecule. Bind-
ing of these basic proteins could alter the electrostatic surface
potential near the crystals. The positive surface potential of the
protein molecule repels cations and could result in a lower local
Fig. 4. Effect of IaI or its derivatives on crystal growth and
aggregation in a seeded metastable solution of CaOx. (A) Effect of UTI
on CaOx crystal growth, expressed as the increase in crystal diameter by
flow cytometry. Panel 1, UTI concentration 5 0 mM and CaOx crystal
diameter 5 40.6 mm; panel 2, 0.2 mM and 15.3 mm; panel 3, 1.0 mM and
2.40 mm; panel 4, 5.0 mM and 2.01 mm; panel 5, 25 mM and 1.64 mm;
panel 6, 100 mM and 1.93 mm. Particle diameter standards are shown on
the far right. Data shown are from a single representative of three
separate experiments. (B) The change of relative CaOx crystal growth
was plotted in relation to the concentrations of IaI and its derivatives.
Results are the mean of two experiments, carried out on triplicate
assays; the bar is SD. Symbols are: (h) heavy chains of IaI; (l) IaI;
() HI-8; (f) chondroitinase AC-treated UTI; (V) UTI.
Kobayashi et al: UTI inhibits CaOx crystal growth 1733
concentration of calcium ions [43]. A second possible mechanism
proposes that binding of an inhibitor protein to CaOx crystals
induces a structural change in the CaOx crystals and crystal matrix
proteins, such that the energistics of calcium binding within
crystals are modified. Such an allosteric interaction between the
UTI site and crystal matrix sites for calcium ions could change the
rate-limiting steps of calcium binding. Finally, UTI may act as a
calcium chelator. Nonetheless, the effects of UTI observed here,
and its high natural concentration in urine suggest that it should
still affect the size of CaOx particles formed in vivo, by interdicting
the aggregation of individual crystals into large clusters.
Besides enhancing our understanding that UTI retains a high
affinity binding site for calcium ions, studies of the interaction of
proteins of the IaI family with calcium ions may provide insights
into other types of important protein-calcium channel interac-
tions. In fact, UTI has novel functions including inhibition of
cellular calcium influx [25–27]. For example, the inactivation
process of certain ion channels may be mediated by binding of
UTI to a certain receptor site/GTP-binding proteins [44, 45].
We are currently determining whether the region of the UTI
molecule that interacts with serine proteases is also involved in
binding to the calcium channel. Site-directed mutagenesis of
various residues within the trypsin contact region of UTI should
provide a direct test of this possibility, and this approach is now in
progress.
ACKNOWLEDGMENT
We are grateful to Dr. J. Gotoh for help with flow cytometry.
Reprint requests to Hiroshi Kobayashi, Ph.D., M.D., Department of
Obstetrics and Gynecology, Hamamatsu University School of Medicine,
Handacho 3600, Hamamatsu, Shizuoka, 431-31, Japan.
APPENDIX
Abbreviations used in this article are: BSA, bovine serum albumin;
CaOx, calcium oxalate; CMP, crystal matrix protein; COM, carcium
oxalate monohydrate; HI-8, carboxyl-terminal domain of UTI; IaI, inter-
a-trypsin inhibitor; LPS, lipopolysaccharide; PVDF, polyvinylidine diflu-
oride; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis; TBS, Tris-buffered saline; THP, Tamm-Horsfall protein; UPA,
uronic-acid-rich protein; UTI, urinary trypsin inhibitor.
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